Welcome to our dedicated page for STEMTECH CORPORATION SEC filings (Ticker: STEK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stemtech Corporation's SEC filings document its public-company reporting obligations as a Nevada operating company and OTC-traded issuer. Recent Form 12b-25 notices cover delayed Form 10-K and Form 10-Q reporting tied to preparation of annual and quarterly financial statements.
The filing record identifies the registrant, commission file number and incorporation status, and frames compliance with periodic reporting requirements under the Exchange Act. These disclosures center on reporting timeliness, financial-statement preparation, corporate registration details and related reporting representations.
Stemtech Corporation submitted a Rule 12b-25 notice stating its Form 10-Q for the quarter ended March 31, 2026 could not be filed on time because the company needs additional time to complete the financial statements and prepare the Form 10-Q. The company states it expects to use no more than the additional five calendar days allowed to complete and file the report.
The notice also discloses that the company has not filed its Annual Report on Form 10-K for the fiscal year ended 2025. The 12b-25 was signed by CEO Charles S. Arnold on May 14, 2026.
STEMTECH CORPORATION notified the SEC that its Form 10-Q for the quarter ended March 31, 2026 was not filed on time and expects to use the additional 5 calendar days permitted under Rule 12b-25 to complete and file the report. The notification was signed by Charles S. Arnold, CEO on May 14, 2026.
Stemtech Corporation filed a Form 12b-25 notifying the SEC of a late annual report for the period ended December 31, 2025. The company states the delay was caused by delays in preparation of its annual financial statements. The notice was signed by Charles S. Arnold, CEO on March 31, 2026.
Stemtech Corporation (STEK) reported another loss-making quarter and raised going concern doubts in its Q3 2025 report. For the quarter ended September 30, 2025, net sales were $852,300, down from $1,031,630 a year earlier, as the company shifted away from lower-margin volume toward core markets. Despite lower revenue, cost controls helped reduce operating loss to $339,217 from $716,470, and net loss narrowed to $812,541 from $1,171,405.
For the nine months, sales fell to $2,418,271 from $3,740,000, but net loss improved to $2,567,547 from $3,376,121 as operating expenses declined by about $1.3 million. The balance sheet remains strained: assets were $3,755,801 against current liabilities of $10,301,779, resulting in a stockholders’ deficit of $6,545,978 and a working capital deficit of about $9.2 million.
Management explicitly concluded that substantial doubt about the company’s ability to continue as a going concern is not alleviated, citing recurring losses, negative operating cash flow, dependence on external financing, and defaults under certain Merchant Cash Advance agreements now in litigation. Stemtech is pursuing private equity raises, a proposed convertible debt facility, cost cuts, and international joint ventures to improve liquidity, but these plans are not yet committed or realized.
Stemtech Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing of its quarterly report for the period ended September 30, 2025. The company cites delays in preparing its quarterly financial statements as the reason.
The notification lists Charles Arnold, CEO, as the signatory and provides a company contact at (954) 715-6000. The notice was signed on November 14, 2025.